East Rutherford – October 30, 2026 -- Cambrex has started construction on a $120 million expansion at its Charles City, Iowa, facility, adding 160,000 liters of manufacturing capacity for small molecule active pharmaceutical ingredients (APIs) and synthetic peptides.

Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

Rochester, N.Y. -- AeroSafe Global will host a virtual Sustainability Symposium on November 10, 2026, to present closed-loop reuse systems for cold-chain packaging that it says can cut landfill waste by up to 95%.

Boston – October 30, 2026 -- Bambusa Therapeutics (Nasdaq: BBTX) priced its upsized initial public offering at $16.00 per share, raising expected gross proceeds of $168,888,880 from the sale of 10,555,555 common shares.

SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.

STOCKHOLM – October 30, 2026 -- The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi) proposes Börje Ekholm, who recently stepped down as CEO of Ericsson, as new Board member and Chair at the 2027 Annual General Meeting (AGM). He would succeed David Meek, who has told the committee he will not stand for re-election.

Tustin – October 30, 2026 -- Avid Bioservices, a U.S. mid-scale biologics contract development and manufacturing organization (CDMO), has received the City of Tustin's Business Recognition Award in the Industrial & Manufacturing – Life Sciences category.

Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

North Brunswick, N.J. – October 30, 2026 -- All five antibody-deficient mice treated with Lactiga's LCTG-001 survived influenza infection, compared with two of five in the control group, according to a peer-reviewed preclinical study conducted by McMaster University scientists in collaboration with Lactiga US, Inc.

SAN MATEO – October 29, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech, has launched with Unravel Biosciences as its founding development partner to pursue treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD). Unravel co-founder and CEO Richard Novak, PhD, has joined Astrosalva's board of directors.